Featured Research

from universities, journals, and other organizations

A treatment for one form of albinism?

Date:
September 26, 2011
Source:
Journal of Clinical Investigation
Summary:
Individuals with oculocutaneous albinism, type 1 (OCA1) have white hair, very pale skin, and light-colored irises. Affected individuals have impaired eyesight and a substantially increased risk of skin cancer. Current treatment options are limited to attempts to correct eyesight and counseling to promote the use of sun protective measures. However, researchers have now generated data in mice that provide hope for a new treatment for a subset of patients with OCA1.

Individuals with oculocutaneous albinism, type 1 (OCA1) have white hair, very pale skin, and light-colored irises because they have none, or very little, of the pigment melanin in their skin, hair, and eyes. Affected individuals have impaired eyesight and a substantially increased risk of skin cancer. Current treatment options are limited to attempts to correct eyesight and counseling to promote the use of sun protective measures.

Related Articles


A team of researchers, led by Brian Brooks, at the National Eye Institute, Bethesda, has now generated data in mice that provide hope for a new treatment for a subset of patients with OCA1.

OCA1 is caused by mutations in the gene Tyr that result in either complete loss of activity of the protein tyrosinase (which is key to the generation of melanin) or the generation of a tyrosinase protein with reduced activity. Brooks and colleagues found that treating mice that model OCA1 caused by mutations that generate a tyrosinase protein with reduced activity (OCA-1B) with nitisinone, which is already FDA-approved for treating a blood condition known as hereditary tyrosinemia type 1, increases their eye and hair pigmentation. They therefore suggest that nitisinone could improve pigmentation in patients with OCA-1B and potentially ameliorate their vision loss.

In an accompanying commentary, Seth Orlow and Prashiela Manga, at New York University School of Medicine, New York, discuss the inspired study of Brooks and colleagues but caution that there are issues that might limit the use of nitisinone as a treatment for OCA-1B.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ighovie F. Onojafe, David R. Adams, Dimitre R. Simeonov, Jun Zhang, Chi-Chao Chan, Isa M. Bernardini, Yuri V. Sergeev, Monika B. Dolinska, Ramakrishna P. Alur, Murray H. Brilliant, William A. Gahl, Brian P. Brooks. Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism. Journal of Clinical Investigation, 2011; DOI: 10.1172/JCI59372

Cite This Page:

Journal of Clinical Investigation. "A treatment for one form of albinism?." ScienceDaily. ScienceDaily, 26 September 2011. <www.sciencedaily.com/releases/2011/09/110926131748.htm>.
Journal of Clinical Investigation. (2011, September 26). A treatment for one form of albinism?. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2011/09/110926131748.htm
Journal of Clinical Investigation. "A treatment for one form of albinism?." ScienceDaily. www.sciencedaily.com/releases/2011/09/110926131748.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins